Search Within

Angela Kellen Green

  1. "Body Imaging Service"
Formats
  1. Meeting Abstract (3)
  2. Journal Article (1)
Groups
  1. Body Imaging Service (4)
  2. Department of Medicine (4)
  3. GDMT, Medicine (4)
  4. Gynecologic Medicine Service (4)
  5. Gynecology Disease Management Team (4)
  6. Population Sciences Research Program (4)

More Groups

People
  1. Maria Zlobinsky (4)
  2. Vicky Makker (4)
  3. Alexia Iasonos (3)
  4. Carol Aghajanian (3)
  5. Qin Zhou (3)
  6. William Zammarrelli (3)

More People

Years
  1. 2024 (1)
  2. 2023 (2)
  3. 2022 (1)
Publications
  1. Gynecologic Oncology (2)
  2. Journal of Clinical Oncology (2)
Publishers
  1. American Society of Clinical Oncology (2)
  2. Elsevier Inc. (2)

Results (4)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer
    Meeting Abstract

    Green, A.; Zhou, Q.; Iasonos, A.; Zammarrelli, W.; Weigelt, B.; Ellenson, L. H.; Chhetri-Long, R.; Shah, P.; Hom, V.; Erinjeri, J. P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real-world outcomes and adverse events when using combination lenvatinib and pembrolizumab for the treatment of recurrent uterine cancer
    Meeting Abstract

    Zammarrelli, W.; Ma, W.; Espino, K.; Yeoshoua, E.; Ehmann, S.; Zhou, Q.; Iasonos, A.; Abu-Rustum, N.; Aghajanian, C.; Green, A.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer
    Journal Article

    Zammarrelli, W. A. 3rd; Ma, W.; Espino, K.; Gordhandas, S.; Yeoshoua, E.; Ehmann, S.; Zhou, Q.; Iasonos, A.; Abu-Rustum, N. R.; Aghajanian, C.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)
    Meeting Abstract

    Kyi, C.; Rubinstein, M. M.; Shah, P.; Zhou, Q.; Iasonos, A.; Liu, Y.; Ramirez, L.; Paroder, V.; Green, A.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save